INTANGIA TRIAGE LAYER · RETROSPECTIVELY VALIDATED
A clearer shortlist for what to investigate next.
Intangia helps R&D teams prioritise target, indication, and mechanism opportunities before they become obvious, so scientific and strategy teams can direct their review time where it matters most.
THE TRIAGE PROBLEM
The best next programme
is rarely obvious
For every target, disease area, or mechanism, there may be hundreds or thousands of possible relationships to explore. Evidence is distributed across publications, patents, and clinical activity, and most potential opportunities will never translate into a programme. The constraint is not access to information. It is knowing where to direct limited scientific, strategic, and portfolio attention.
Too many plausible directions
A broad research landscape quickly becomes impossible to review consistently.
Signals emerge before consensus
The earliest evidence is often fragmented, weak on its own, and easy to miss.
Expert time is limited
Teams need a defensible way to decide what to investigate now, monitor, or deprioritise.
FROM QUESTION TO SHORTLIST
Start with a question.
End with a focused next step.
Choose a focal question.
A focal area might be a target, mechanism, disease, or modality. Intangia begins by mapping the relationships around it that could become relevant programme opportunities.
See the full opportunity landscape
Every focal area connects to a much larger field of potential target–indication, target–target, or mechanism relationships. Most are not worth pursuing, but identifying the few that are is difficult.
Identify the signals beginning to converge
Scientific publications, patent activity, and clinical precedent each reveal part of the picture. Intangia brings these dated signals into one view, helping teams see which relationships are gathering momentum.
Get a reviewable shortlist
The triage layer ranks the relationships that warrant closer investigation and retains the evidence behind each one. It does not replace expert judgement; it makes expert review more focused, consistent, and traceable.
PREPRINT HIGHLIGHTS
A more focused shortlist changes
what your team can review.
The Intangia triage layer was retrospectively evaluated using point-in-time public evidence across 100 focal areas. The study asked a practical question: at a fixed review depth, how often did shortlisted relationships later enter a registered clinical trial?
1 in 4
Top-20 shortlisted opportunities entering clinical trials within four years
38
x
More concentrated than a matched baseline shortlist
2–3
years
Median lead time before first trial
100
Focal areas
Tested across seven therapeutic domains
What this enables for R&D teams
Focus expert review where it matters
Move from a long list of possible programmes to a prioritised set of opportunities that warrant scientific and strategic attention.
Compare opportunities consistently
Apply the same evidence-led approach across targets, indications, and modalities—rather than relying on fragmented research or individual narratives.
Act earlier, with a clearer rationale
See which opportunities are building momentum and document why a programme should be pursued, watched, or deprioritised.
